• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

招募具有溴结构域 1 选择性配体的 BET 蛋白的“金发姑娘区域”。

A "Goldilocks Zone" for Recruiting BET Proteins with Bromodomain-1-Selective Ligands.

机构信息

Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.

Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.

出版信息

ACS Chem Biol. 2024 Nov 15;19(11):2268-2276. doi: 10.1021/acschembio.4c00505. Epub 2024 Oct 14.

DOI:10.1021/acschembio.4c00505
PMID:39401417
Abstract

Synthetic genome readers/regulators (SynGRs) are bifunctional molecules that are rationally designed to bind specific genomic sequences and engage cellular machinery that regulates the expression of targeted genes. The prototypical SynGR1 targets GAA trinucleotide repeats and recruits the BET family of transcriptional regulatory proteins via a flexibly tethered ligand, JQ1. This pan-BET ligand binds both tandem bromodomains of BET proteins (BD1 and BD2). Second-generation SynGRs, which substituted JQ1 with bromodomain-selective ligands, unexpectedly revealed that BD1-selective ligands failed to functionally engage BET proteins in living cells despite displaying the ability to bind BD1 in vitro. Mechanistically, recruiting a BET protein via BD1- or BD2-selective SynGRs should have resulted in indistinguishable functional outcomes. Here we report the conversion of inactive BD1-targeting SynGRs into functional gene regulators by a structure-guided redesign of the chemical linker that bridges the DNA-binding molecule to the highly selective BD1 ligand GSK778. The results point to an optimal zone for positioning the BD1-selective ligand for functional engagement of BET proteins on chromatin, consistent with the preferred binding of BD1 domains to distal acetyllysine residues on histone tails. The results not only resolve the mechanistic conundrum but also provide insight into domain-selective targeting and nuanced design of chemo probes and therapeutics.

摘要

合成基因组读取器/调节剂(SynGRs)是一种双功能分子,经过合理设计可与特定基因组序列结合,并激活细胞机制来调节靶向基因的表达。原型 SynGR1 靶向 GAA 三核苷酸重复序列,并通过柔性连接的配体 JQ1 招募 BET 家族转录调节蛋白。这种泛 BET 配体结合 BET 蛋白的两个串联溴结构域(BD1 和 BD2)。第二代 SynGRs 用溴结构域选择性配体替代了 JQ1,但出乎意料的是,尽管第二代 SynGRs 具有体外结合 BD1 的能力,但它们的 BD1 选择性配体在活细胞中未能有效地与 BET 蛋白结合。从机制上讲,通过 BD1 或 BD2 选择性 SynGR 招募 BET 蛋白应该会产生相同的功能结果。在这里,我们通过对连接 DNA 结合分子和高度选择性 BD1 配体 GSK778 的化学连接子进行结构指导重新设计,将无活性的 BD1 靶向 SynGR 转化为功能性基因调节剂。结果表明,BD1 选择性配体在染色质上与 BET 蛋白进行功能结合的最佳位置,与 BD1 结构域与组蛋白尾部远端乙酰赖氨酸残基的优先结合一致。该结果不仅解决了机制难题,还为化学探针和治疗剂的结构域选择性靶向和细微设计提供了新的思路。

相似文献

1
A "Goldilocks Zone" for Recruiting BET Proteins with Bromodomain-1-Selective Ligands.招募具有溴结构域 1 选择性配体的 BET 蛋白的“金发姑娘区域”。
ACS Chem Biol. 2024 Nov 15;19(11):2268-2276. doi: 10.1021/acschembio.4c00505. Epub 2024 Oct 14.
2
Domain-Selective BET Ligands Yield Next-Generation Synthetic Genome Readers/Regulators with Nonidentical Cellular Functions.结构域选择性BET配体产生具有不同细胞功能的下一代合成基因组读取器/调节剂。
J Am Chem Soc. 2023 Nov 3. doi: 10.1021/jacs.3c06297.
3
Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.发现并鉴定 BRDT 的溴结构域 2 特异性抑制剂。
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9). doi: 10.1073/pnas.2021102118.
4
Lysine-Targeting, Covalent Inhibitors of Bromodomain BD1 of BET Proteins in Live Cells and Animals.赖氨酸靶向的BET蛋白溴结构域BD1在活细胞和动物中的共价抑制剂
Angew Chem Int Ed Engl. 2025 May 1:e202424832. doi: 10.1002/anie.202424832.
5
Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.溴结构域蛋白 4(BRD4)与组蛋白 H4 尾部和小分子抑制剂 JQ1 的相互作用亲和图。
J Biol Chem. 2014 Mar 28;289(13):9304-19. doi: 10.1074/jbc.M113.523019. Epub 2014 Feb 4.
6
Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system.在基因互补系统中对溴结构域和末端结构域(BET)蛋白进行比较结构-功能分析。
J Biol Chem. 2020 Feb 14;295(7):1898-1914. doi: 10.1074/jbc.RA119.010679. Epub 2019 Dec 2.
7
BRD4 inhibition rewires cardiac macrophages toward a protective phenotype marked by low MHC class II expression.BRD4抑制可使心脏巨噬细胞重编程为以低MHC II类表达为特征的保护性表型。
Am J Physiol Heart Circ Physiol. 2025 Feb 1;328(2):H294-H309. doi: 10.1152/ajpheart.00438.2024. Epub 2024 Dec 23.
8
BET degraders reveal BRD4 disruption of 7SK and P-TEFb is critical for effective reactivation of latent HIV in CD4+ T-cells.BET降解剂揭示BRD4对7SK和P-TEFb的破坏对于CD4 + T细胞中潜伏HIV的有效重新激活至关重要。
J Virol. 2025 Apr 15;99(4):e0177724. doi: 10.1128/jvi.01777-24. Epub 2025 Mar 11.
9
Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.溴结构域和末端外结构域家族(BET)蛋白的结构选择性抑制剂的研究进展。
Eur J Med Chem. 2021 Dec 15;226:113853. doi: 10.1016/j.ejmech.2021.113853. Epub 2021 Sep 13.
10
Design and Evaluation of Novel Selective BET BD2 Inhibitors by Combining QSAR, Molecular Docking and Molecular Dynamics Simulation Techniques.结合定量构效关系、分子对接和分子动力学模拟技术对新型选择性BET BD2抑制剂的设计与评估
Chem Biodivers. 2025 Jun;22(6):e202403038. doi: 10.1002/cbdv.202403038. Epub 2025 Feb 4.

引用本文的文献

1
A Minireview on BET Inhibitors: Beyond Bromodomain Targeting.BET抑制剂综述:超越溴结构域靶向作用
Biomedicines. 2025 Mar 1;13(3):594. doi: 10.3390/biomedicines13030594.

本文引用的文献

1
Accurate structure prediction of biomolecular interactions with AlphaFold 3.利用 AlphaFold 3 进行生物分子相互作用的精确结构预测。
Nature. 2024 Jun;630(8016):493-500. doi: 10.1038/s41586-024-07487-w. Epub 2024 May 8.
2
Using synthetic genome readers/regulators to interrogate chromatin processes: A brief review.利用合成基因组读取器/调节剂来探究染色质过程:简要综述。
Methods. 2024 May;225:20-27. doi: 10.1016/j.ymeth.2024.03.001. Epub 2024 Mar 11.
3
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review.
BD1 选择性 BET 抑制剂研发的成功与挑战:专利述评。
Expert Opin Ther Pat. 2024 Jul;34(7):529-545. doi: 10.1080/13543776.2024.2327300. Epub 2024 Mar 11.
4
Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia.发现新型苯氧嘧啶并吡啶酮类作为溴结构域和额外末端结构域(BET)抑制剂,对第二个溴结构域(BD2)具有高选择性,可能用于治疗急性髓细胞白血病。
J Med Chem. 2024 Jan 25;67(2):1513-1532. doi: 10.1021/acs.jmedchem.3c02104. Epub 2024 Jan 4.
5
Domain-Selective BET Ligands Yield Next-Generation Synthetic Genome Readers/Regulators with Nonidentical Cellular Functions.结构域选择性BET配体产生具有不同细胞功能的下一代合成基因组读取器/调节剂。
J Am Chem Soc. 2023 Nov 3. doi: 10.1021/jacs.3c06297.
6
Current strategies for the design of PROTAC linkers: a critical review.PROTAC连接子设计的当前策略:批判性综述。
Explor Target Antitumor Ther. 2020;1(5):273-312. doi: 10.37349/etat.2020.00018. Epub 2020 Oct 30.
7
Alternative Mechanisms for DNA Engagement by BET Bromodomain-Containing Proteins.BET 溴结构域蛋白与 DNA 结合的其他机制。
Biochemistry. 2022 Jul 5;61(13):1260-1272. doi: 10.1021/acs.biochem.2c00157. Epub 2022 Jun 24.
8
Premature transcription termination at the expanded GAA repeats and aberrant alternative polyadenylation contributes to the Frataxin transcriptional deficit in Friedreich's ataxia.扩张的 GAA 重复序列处过早转录终止和异常的可变多聚腺苷酸化导致弗里德里希共济失调症中 Frataxin 的转录缺陷。
Hum Mol Genet. 2022 Oct 10;31(20):3539-3557. doi: 10.1093/hmg/ddac134.
9
A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles.BET蛋白的生物化学、生理学及病理作用综述
Front Pharmacol. 2022 Mar 25;13:818891. doi: 10.3389/fphar.2022.818891. eCollection 2022.
10
Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development.药物研发中靶向BET蛋白的溴结构域选择性抑制剂
J Med Chem. 2022 Apr 14;65(7):5184-5211. doi: 10.1021/acs.jmedchem.1c01835. Epub 2022 Mar 24.